Showing results (181-190 of 331) with videos related to
Sort By:
Pageof 34
Clinical Hematology International|November 25, 2021
High Sensitivity Troponin T and NT-proBNP in Patients Receiving Chimeric Antigen Receptor (CAR) T-Cell TherapyJiun-Ruey Hu, Ameet Patel, Shi Huang, et al.Journal of Investigative Medicine : the Official Publication of the American Federation for Clinical Research|February 5, 2021
Long-term progression-free survival of patients with metastatic melanoma or renal cell carcinoma following high-dose interleukin-2Joseph I Clark, Brendan Curti, Elizabeth J Davis, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 7, 2014
Beyond histology: translating tumor genotypes into clinically effective targeted therapiesCatherine B Meador, Christine M Micheel, Mia A Levy, et al.Cancer Cell|February 11, 2025
Genomic mediators of acquired resistance to immunotherapy in metastatic melanomaJulia Schiantarelli, Mouadh Benamar, Jihye Park, et al.Cancer Immunology Research|April 12, 2017
Clinical Features of Acquired Resistance to Anti-PD-1 Therapy in Advanced MelanomaDaniel Y Wang, Zeynep Eroglu, Alpaslan Ozgun, et al.Pigment Cell & Melanoma Research|November 25, 2017
BRAF internal deletions and resistance to BRAF/MEK inhibitor therapyDouglas B Johnson, Merrida A Childress, Zachary R Chalmers, et al.Cancer Immunology Research|August 30, 2019
Anti-PD-1-Induced Pneumonitis Is Associated with Persistent Imaging Abnormalities in Melanoma PatientsDouglas B Johnson, Kevin B Taylor, Justine V Cohen, et al.JAMA Oncology|July 19, 2019
Comparison of Biomarker Modalities for Predicting Response to PD-1/PD-L1 Checkpoint Blockade: A Systematic Review and Meta-analysisSteve Lu, Julie E Stein, David L Rimm, et al.Journal for Immunotherapy of Cancer|July 7, 2022
Efficacy and safety of anti-PD1 monotherapy or in combination with ipilimumab after BRAF/MEK inhibitors in patients with BRAF mutant metastatic melanomaInes Pires da Silva, Danny Zakria, Tasnia Ahmed, et al.Ebiomedicine|October 15, 2017
MDM2 Antagonists Counteract Drug-Induced DNA DamageAnna E Vilgelm, Priscilla Cobb, Kiran Malikayil, et al.Pageof 34